Closed
Save

Synthesis of Prodrug Analogs and Cyclopentane Peptide Nucleic Acid Precursors

Health & Human Services (HHS) > NIHSol: 75N98026Q00819CREAGENINC
est. $25K – $120K

This opportunity is closed

The response deadline has passed. Review the details for future reference or to track similar opportunities.

Quick Brief

The Department of Health and Human Services is procuring the synthesis of prodrug analogs and cyclopentane peptide nucleic acid precursors to support biomedical research conducted by the National Institute of Diabetes and Digestive and Kidney Diseases. Key requirements include custom synthesis, purification, and characterization of specialized precursor materials that are not commercially available, which will be used in preclinical studies for cancer and HIV treatment development.

Generated 7d ago

Contract Details

Estimated Value
est. $25K – $120K
Similar contracts award $15K to $88K (median $25K, 1,242 awards)Within typical range
NAICS Codes
Place of Performance
BETHESDA, MD, USA

Agency & Contact

Contracting Organization

Agency
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-Agency
NATIONAL INSTITUTES OF HEALTH - DRUGS AND BIOLOGICALS

Point of Contact

John A. Smith
Contracting Officer
(202) 555-0100

Key Dates

Response Date20d ago
Jul 5, 202609:00 AM EDT
Response Due19d ago
Jul 5, 2026
Published9d ago
Jul 16, 2026
Became Solicitation8d ago
Jul 16, 2026
Tracked
Last Updated7d ago
Jul 17, 2026

Description

The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports biomedical research to improve the understanding, prevention, and treatment of diseases affecting human health. Within the Laboratory of Bioorganic Chemistry, the Synthetic Bioactive Molecules Section conducts research focused on the discovery and development of novel therapeutic compounds for the treatment and prevention of cancer and HIV infection. Ongoing studies have identified several promising sulfanylbenzamide-derived compounds and cyclopentane peptide nucleic acid precursor materials with potential applications as anti-cancer therapeutics, HIV prevention and treatment agents, and diagnostic technologies. To support these research efforts, the Synthetic Bioactive Molecules Section requires synthesis scale-up, custom synthesis, purification, and characterization of optimized lead compounds and specialized precursor materials. These materials are not commercially available and require specialized synthetic expertise and production capabilities to generate quantities sufficient for continued preclinical evaluation. The materials produced under this requirement will be used in ongoing preclinical studies to evaluate compound activity, optimize lead candidates, and support advancement toward future clinical development. Vishnuvajjala Hanumanth Rao Contracting ., SUITE 503L (No Street Address

2) BETHESDA, MD 20892 USA to this opportunity.

Get matched to contracts like this daily

Free AI-powered contract matching for your business.